Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer

Mi Ran Yun(Yonsei University), Byoung Chul Cho(Yonsei University), Seong Gu Heo(Yonsei University), Hyo Sup Shim(Yonsei University), You Won Lee(Yonsei University), Hye Ryun Kim(Yonsei University), Seok‐Gu Kang(Yonsei University), Alexander Drilon(Memorial Sloan Kettering Cancer Center), J. Jean Cui(Southern Medical University), Seok‐Young Kim(Oncode Institute), Hun Mi Choi(Yonsei University), Dong Hwi Kim, Han Na Kang(Yonsei University), Sung Sook Lee(Inje University Haeundae Paik Hospital), Hyeong-Seok Joo(Jeuk (South Korea)), Adam J. Schoenfeld(Memorial Sloan Kettering Cancer Center), Chae Won Park(Yong In University), Min Hee Hong(Yonsei University)
Clinical Cancer Research
April 13, 2020
10.1158/1078-0432.ccr-19-2777
Cited by 116

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
|Nature Medicine|2015|1.5k
Acquired Resistance to Immune Checkpoint Inhibitors
|Cancer Cell|2020|927
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924